Biotechnology company Elicera Therapeutics AB (publ) announced on Monday that its drug candidate ELC-100 has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for treating pancreatic neuroendocrine tumours.
ODD supports the development of treatments for rare diseases, with benefits including tax credits for US clinical trials and potential fee waivers for marketing approval. In addition, ODD provides up to seven years of market exclusivity upon approval.
ELC-100 is based on an oncolytic virus and targets neuroendocrine cancer cells selectively. Elicera is currently conducting a Phase I/II trial to determine the maximum tolerated dose (MTD) and assess safety. The company completed patient recruitment for the trial's first part in fall 2024. Final data from this phase is expected in mid-2025.
Organon acquires US rights to TOFIDENCE from Biogen
Oncopeptides secures FDA approval to resume OPD5 clinical development
Bonesupport submits FDA application for CERAMENT V
Spinogenix starts enrolment for SPG302 Phase 2 trial in schizophrenia
DDL opens new GMP laboratory for drug-device combination product testing
Langhua Pharmaceutical passes US FDA's on-site inspection
PTC Therapeutics announces opinion regarding Translarna's (ataluren) European renewal authorisation
Soleno Therapeutics selects PANTHERx Rare as specialty pharmacy for VYKAT XR distribution